Ropinirole
Alternative Names: Adartrel; Repreve; Requip; Ropinirole immediate-release; Ropinirole IRLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Amines; Antiparkinsonians; Indoles; Sleep disorder therapies; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Parkinson's disease; Restless legs syndrome
- No development reported Fibromyalgia
Most Recent Events
- 20 May 2015 No development reported - Phase-III for Parkinson's disease (Adjunctive treatment) in China (PO)
- 06 Dec 2006 Launched for Parkinson's disease in Japan (PO)
- 07 Apr 2006 The European Commission has adopted a positive decision on the marketing authorisation application of ropinirole for restless leg syndrome in the EU